Better understanding of cell-to-cell and cellto-extracellular matrix interactions has led to the use of 3-dimensional clusters, which are physiologically more relevant than single cell-based or two-dimensional approaches. In-vitro 3D-culturing allows tumor cell clusters to form complex 3D-microtumors that recapitulate the in-vivo architecture and genetic signature of original tumor tissues². Despite recent progress, across all cancers, only an estimated 7% of patients tested for genetic biomarkers can ultimately benefit from this genetic information¹. As a powerful, proven platform, functional drug sensitivity testing (f-DST) offers highquality assessment and comparison of responses among anticancer drugs of interest³. Functional drug sensitivity testing on the patient’s own 3D-microtumors therefore complements existing diagnostic efforts and Patient-derived tumor cells have shown great potential for basic and translational research and drug discovery1. Functional Drug Sensitivity Testing
RkJQdWJsaXNoZXIy ODY1MjQ=